Related Experiment Video
Updated: May 27, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond
J W Mandema1, M Gibbs, R A Boyd
1Quantitative Solutions, Inc., Menlo Park, California, USA. jmandema@wequantify.com
Abstract:
High development cost, low development success, cost-disciplined health-care policies, and intense competition demand an efficient drug development process. New compounds need to bring value to patients by being safe, efficacious, and cost-effective as compared with existing treatment options. Model-based meta-analysis (MBMA) facilitates integration and utilization of summary-level efficacy and safety data, providing a quantitative framework for comparative efficacy and safety assessment. This Commentary discusses the application and limitations of MBMA in drug development.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Measurement of Bioavailability: Pharmacodynamic Methods
Analysis of Population Pharmacokinetic Data
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model